We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

AC Immune's robust pipeline

Our robust and diverse pipeline of seven therapeutic and three diagnostic product candidates has the potential to greatly improve the treatment of a broad spectrum of Alzheimer’s and neurodegenerative diseases. All of the company’s products were discovered utilizing its proprietary SupraAntigen™ and Morphomer™ technology platforms.

Crenezumab (anti-Abeta antibody)
AD treatment
Phase 3
Biologics
AD prevention
Phase 2
Biologics
ACI-24 (anti-Abeta vaccine)
AD treatment
Phase 2
Biologics
ACI-35 (anti-pTau vaccine)
AD treatment
Phase 1
Biologics
Anti-Tau antibody
AD treatment
Phase 2
Biologics
Morphomer Tau (Tau inhibitor)
AD treatment
Discovery
Small molecules
ACI-24 (anti-Abeta vaccine)
Down syndrome*
Phase 1
Biologics
Morphomer Abeta (Abeta inhibitor)
Glaucoma
Pre-clin.
Small molecules
Morphomer α-syn (α-synuclein inhibitor)
Parkinson's
Discovery
Small molecules
Anti α–synuclein antibody
Discovery
Biologics
Anti TDP-43 antibody
Discovery
Biologics
Tau-PET imaging agent
AD diagnostic
Phase 1
Diagnostics
In-Vitro Diagnostics (Tau, Abeta)
AD diagnostic
Pre-clin.
Diagnostics
α-synuclein-PET imaging agent
Parkinson's diagnostic
Pre-clin.
Diagnostics